Cephalon/CIMA Merger Clears FTC: Generic Actiq To Ensure Price Competition
Executive Summary
The Federal Trade Comission has taken the unprecedented step of allowing a brand name pharmaceutical manufacturer to establish a generic alternative for a drug rather than divest it to ensure market competition
You may also be interested in...
Cephalon Bolstering Sales Force Ahead Of Multiple Launches Expected In ‘06
Cephalon is actively recruiting representatives for what could become three separate sales forces to support multiple new product launches in 2006
Cephalon Bolstering Sales Force Ahead Of Multiple Launches Expected In ‘06
Cephalon is actively recruiting representatives for what could become three separate sales forces to support multiple new product launches in 2006
Cephalon Preps For Provigil Label Expansion, Wins Bid For CIMA
Cephalon is enlarging its sales force to 500 reps in anticipation of FDA approval for an expanded wakefulness indication for Provigil, CEO Frank Baldino told analysts Nov. 3